MSN Group has launched generic palbociclib tablets, 75 mg, 100 mg and 125 mg for advanced breast cancer therapy under the brand name Palborest, a statement from the company informed yesterday.
Priced at Rs 257.14/tablet for 125 mg, Rs 233.28/tablet for 100 mg, Rs 214.29/tablet for 75 mg respectively, Palborest is more affordable and bioequivalent to innovator tablet. The tablet dosage form offers distinct advantage over capsule dosage form as they can be taken with or without food. These tablets can be co-administered with Proton Pump Inhibitors (PPIs) or antacids. The tablet formulation does not contain lactose (dairy) or gelatin, which also contributes to the efficacy of the drug, it said.
The statement further mentioned that Palborest comes in a patient-compliant pack of three strips of seven tablets each to meet the recommended three-weeks on, one-week off-treatment schedule.
According to the statement, Palbociclib is approved by the United States Food and Drug Administration (USFDA), the European Medicines Agency (EMA) and the Central Drugs Standard Control Organization (CDSCO), in combination with hormonal therapies for patients with hormone receptor positive, human epidermal growth factor receptor negative locally advanced or metastatic breast cancer.
The product wholly developed and manufactured in-house, from Active Pharma Ingredient (API) to formulation, in USFDA/European Union (EU)-approved facilities, allows MSN Group to ensure seamless access to quality medicine at economical costs, concluded the statement.
Good article an excellent way to articulate. Keep it up